Filgrastim
From Wikipedia, the free encyclopedia
 |
|
|
Filgrastim
|
|
| Systematic (IUPAC) name | |
| Human granulocyte colony stimulating factor | |
| Identifiers | |
| CAS number | |
| ATC code | L03 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C845H1343N223O243S9 |
| Mol. mass | 18802.8 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes.[1] It is produced by recombinant DNA technology. The gene for human granulocyte colony-stimulating factor is inserted into the genetic material of Escherichia coli. The G-CSF then produced by E. coli is only slightly different from G-CSF naturally made in humans.
It is marketed by Amgen with the brand name Neupogen.
Contents |
[edit] Therapeutic uses
Filgrastim is used to treat neutropenia (a low number of neutrophils), stimulating the bone marrow to increase production of neutrophils. Causes of neutropenia include chemotherapy and bone marrow transplantation.
Filgrastim is also used to increase the number of hematopoietic stem cells in the blood before collection by leukapheresis for use in hematopoietic stem cell transplantation.
[edit] Contraindications
Filgrastim should not be used in patients with known hypersensitivity to E. coli-derived proteins.
[edit] Adverse effects
The most commonly observed adverse effect is mild-to-moderate bone pain after repeated administration and local skin reactions at the site of injection.
[edit] References
- ^ Beveridge RA, Miller JA, Kales AN, et al (1998). "A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression". Cancer Invest. 16 (6): 366–73. doi:. PMID 9679526.
- Budiono Santoso; Chris J. van Boxtel; Boxtel, Christoffel Jos van (2001). Drug benefits and risks: international textbook of clinical pharmacology. New York: Wiley. ISBN 0-471-89927-5.
- "Neupogen Prescribing Information." http://www.neupogen.com/pi.html. Accessed 10/20/05.
|
|||||||||||||||||
